Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
ATTRUBY (acoramidis hydrochloride) is an oral small-molecule tablet approved by the FDA on November 22, 2024. The specific indication and mechanism of action are not publicly detailed in available data; however, the drug represents a novel chemical entity entering the market. Patient populations and therapeutic use will depend on the indication for which it was approved.
ATTRUBY is in early growth phase post-launch with no direct competitors, positioning the brand team for market development and team expansion opportunities.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
BridgeBio Pharma is hiring 10 roles related to this product
Worked on ATTRUBY at BridgeBio Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
ATTRUBY is actively hiring across 74 linked positions, with strong demand in Quality Assurance, Commercial, and Data Management roles reflecting a newly launched product requiring infrastructure and market development. Career opportunities span regulatory affairs, commercial operations, and analytical functions with scope for growth as the brand matures through its lifecycle.
74 open roles linked to this drug
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo